RxDoctor Payments Data

Mosbah Kreimid, MD

Pulmonary Disease · Springfield, MONPI 1558347237

Payments from drug & device makers

$2,134in general payments, 2019–2025

Across 122 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$553
  • GSK$378
  • Boehringer Ingelheim$168
  • AbbVie$138
  • Grifols USA, LLC$95
  • Sanofi$88
  • plus $714 from 19 others

What the payments were for

  • Food & beverage$2,11499%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,134 in reported general payments places this provider in the 50th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$56,152
Medicare patients
320
Services billed
843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter980$733,059
Spiriva RespimatTiotropium Bromide243$158,823
FarxigaDapagliflozin Propanediol206$127,947
Stiolto RespimatTiotropium Br/Olodaterol Hcl116$63,681
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr120$62,369
Breztri AerosphereBudesonide/Glycopyr/Formoterol61$43,094
XolairOmalizumab16$38,010
SymbicortBudesonide/Formoterol Fumarate92$31,190
AbrysvoRsv Vacc, Pref A And Pref B/Pf88$24,342
Breo ElliptaFluticasone/Vilanterol55$22,276
Pirfenidone25$18,104
EliquisApixaban24$17,383
Fluticasone-SalmeterolFluticasone Propion/Salmeterol152$16,134
Combivent RespimatIpratropium/Albuterol Sulfate22$15,242
Tadalafil13$14,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arexvy$378$840,9631,225 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$168$237,746381 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Bevespi Aerosphere$553$207,806373 claims
PfizerAbrysvo, Eliquis$34$41,724112 claims
MerckDulera$21$4,02511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →